Loading
Latest filing published 18 Sept 2026 for SAB Biotherapeutics, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Alexandra Kropotova in SAB Biotherapeutics, Inc., where the filings describe the role as senior executive. The record holds 9 filings, for trades running from 6 June 2022 to 17 September 2026.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The newest entry dates from 18 September 2026: a share grant, in SAB Biotherapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations